MetaCap

Repligen Corporation (RGEN)

NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

163.81-6.48 (-3.81%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RGEN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$10.47B
EPS (TTM)
-$0.21
52-week range
100.99 – 198.87
Day range
162.50 – 169.61
Volume / Avg
697.68K / 1.17M
Beta
—

52-week range

$100.99$198.87

RGEN stock today

On Nov 20, RGEN ended the session at $163.81, shedding $6.48 (3.81%), versus the S&P 500's 3.70% decline. At this level, RGEN sits in the middle of its 52-week range of $100.99 to $198.87: 17.6% below the high, set on Sep 28, 2026 and 62.2% above the low. RGEN is down 0.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 0.8%.

Repligen has posted a net loss over the last twelve months (EPS of -$0.21), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Repligen

Company profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Olivier Loeillot
Headquarters
Waltham, MA
Employees
2,000
IPO year
1986

Financial highlights

Full financials

In fiscal 2025, Repligen generated $738.3 million in revenue, up 16.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $48.9 million, for a net margin of 6.6% versus a median of 16.4% in the prior 5 years. Gross margin was 52.3% (up from 43.3%) and operating margin 7.5%.

Repligen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$738.26M$634.44M$632.36M$801.54M$670.53M
Growth+16.36%+0.33%-21.11%+19.54%+83.08%
Net income$48.89M$-25.51M$35.60M$185.96M$128.29M
EPS (diluted)$0.86$-0.46$0.63$3.24$2.24

Analyst forecast

Forecast

Consensus (20 analysts)

buy

Avg. price target

$203.21+24.05%

  • Strong buy 3
  • Buy 13
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $175.00High $235.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 27, 2026
EPS actual vs est.
$0.46 vs $0.46

RGEN news

All RGEN news

Repligen peers

Health Care sector
RGEN peer companies
CompanyPrice% ChgMarket capCompare
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs RGEN
QGENQiagen N.V.49.30-0.66%$10.18Bvs RGEN
KYMRKymera Therapeutics Inc.115.31-3.42%$9.84Bvs RGEN
TECHBio-Techne Corp72.67-0.04%$11.42Bvs RGEN
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs RGEN
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs RGEN
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs RGEN
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs RGEN

Indexes, lists and sector

Repligen stock FAQ

What is Repligen's stock price today?

RGEN last traded at $163.81 as of Nov 20, 4:00 PM EST, down 3.81% on the day. Prices are delayed at least 15 minutes.

Who is Repligen's CEO?

Mr. Olivier Loeillot is the chief executive officer of Repligen Corporation, which has about 2,000 employees.

What is the RGEN 52-week high?

The 52-week high for RGEN is $198.87 and the 52-week low is $100.99. The stock is currently 17.6% below its high.

Compare RGEN